Leerink Partners Continues to View CVS Health (CVS) as a High Quality Stock - Reiterates Outperform
Tweet Send to a Friend
Leerink Partners reiterated an Outperform rating on CVS Health (NYSE: CVS), and cut the price target to $110.00 (from $125.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
